Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Sign Up to like & getrecommendations! Published in 2020 at "Nature Communications"
DOI: 10.1038/s41467-020-15315-8
Abstract: Combined PARP and immune checkpoint inhibition has yielded encouraging results in ovarian cancer, but predictive biomarkers are lacking. We performed immunogenomic profiling and highly multiplexed single-cell imaging on tumor samples from patients enrolled in a… read more here.
Keywords: cd8 cells; immunogenomic profiling; combined parp; exhausted cd8 ... See more keywords
Abstract IA26: Combined PARP and immune checkpoint inhibition in ovarian cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.ovca19-ia26
Abstract: Ovarian cancer (OC) is one of the few malignancies in which immunotherapy with immune checkpoint inhibitors exhibits only modest activity and currently has no FDA-approved indication. Therefore, the development of strategies to improve the efficacy… read more here.
Keywords: immune checkpoint; combined parp; parp immune; ovarian cancer ... See more keywords
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12061502
Abstract: Genomic instability is a hallmark of cancer related to DNA damage response (DDR) deficiencies, offering vulnerabilities for targeted treatment. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) interfere with the efficient repair of DNA damage, particularly in… read more here.
Keywords: immune checkpoint; parp inhibition; parpi; combined parp ... See more keywords